Coronavirus Infected Children Display Strong Antibody Protection

Infants had 13 times higher SARS-CoV-2 antibodies than adults
girl giving her dad a high five
Amanda McConnell from Pixabay
(Coronavirus Today)

A recent study led by researchers at the Johns Hopkins Bloomberg School of Public Health in collaboration with the U.S. Centers for Disease Control and Prevention concluded young children may have strong protection from COVID-19.

In this peer-reviewed study published by the journal JCI Insight on March 22, 2022, infants and toddlers who experienced a SARS-CoV-2 coronavirus infection had significantly higher antibody levels against the virus than adults.

Antibodies to a key site on the virus’s outer spike protein—the “receptor-binding domain” (RBD)—were present at much higher levels in children compared to adults: more than 13 times higher in children age 0-4, and nearly nine times higher in children age 5-17. 

And levels of SARS-CoV-2 neutralizing antibodies, which may help predict protection against severe COVID infection, were nearly twice as high in children ages 0-4 compared to adults.

In most households where both children and adults had antibody evidence of SARS-CoV-2 infection, children ages 0-4 years had the highest levels of SARS-CoV-2 RBD and neutralizing antibodies of all infected household members.   

This analysis is based on samples taken at enrollment from 682 children and adults in 175 Maryland households who participated in a household surveillance study of SARS-CoV-2 infection and had not yet received a COVID-19 vaccine. 

Participants ranged in age from 0 to 62 years, and enrollment samples were collected between November 2020 and March 2021, during the Alpha and Beta virus variants stages.

The researchers found evidence of SARS-CoV-2 antibodies, indicating prior infection with the virus, in 56 people at enrollment. 

Of these 56 people with antibody evidence of previous SARS-CoV-2 infection, 15 were children ages 0 to 4 years, with the youngest three months old; 13 were children ages 5-17 years; 28 were adults ages 18 years or older. 

“This study demonstrates that even children in the first few years of life have the capacity to develop strong antibody responses to SARS-CoV-2 infection, which in some cases exceed adult responses,” says Ruth Karron, MD, lead investigator and a professor in the Department of International Health and director of the Johns Hopkins Vaccine Initiative at the Bloomberg School, in a related press statement.

Karron and colleagues set up their prospective household surveillance study, known as SARS-CoV-2 Epidemiology And Response in Children (SEARCh), to learn more about SARS-CoV-2 infection in children under five years of age, a relatively understudied population.

The analysis of these samples also found that:

  • In the majority of households with SARS-CoV-2-positive children 0-4 years old and other affected household members, the children 0-4 years old had the highest levels of anti-RBD and neutralizing antibodies.
  • 56 (8.2 percent) of the blood samples from 22 households (12.6 percent) contained detectable antibodies against the SARS-CoV-2 (original Wuhan variant) spike protein RBD, indicating prior infection with the virus. Half of the 56 previously infected individuals were children.
  • Only about half of those with RBD antibodies had been previously told by a health care provider that they may have SARS-CoV-2 infection, indicating that many milder or asymptomatic SARS-CoV-2 infections in the community may not be recognized and counted as infection cases. In addition, none of the individuals in the study with previously suspected SARS-CoV-2 infection were hospitalized because of their infections.

“Very young children in our study developed high antibody titers to the SARS-CoV-2 spike protein, which is the target antigen for COVID vaccines,” Karron says. 

“These findings should reassure that with the appropriate vaccine doses, we can effectively immunize very young children against SARS-CoV-2.”

Children ages 5-17 years are currently eligible for the Pfizer-BioNTech mRNA COVID-19 (Comirnaty) vaccine, and studies of the vaccine in younger children are ongoing.

Karron and colleagues continue to analyze follow-up specimens from these 56 individuals and individuals infected during the SEARCh study to learn more about the quality of their SARS-CoV-2 antibody responses and see how durable their antibody is responses are over time.

“Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Very Young Children Exceed Those in Adults” was written by Ruth Karron, Maria Garcia Quesada, Elizabeth Schappell, Stephen Schmidt, Maria Deloria Knoll, Marissa Hetrich, Vic Veguilla, Nicole Doria-Rose, Fatimah Dawood, and other members of the SEARCh Study Team. 

No industry conflicts of interest were disclosed. This study was funded by CDC Award 75D30120C08737.

CoronavirusToday publishes fact-checked and research-based news.

Note: This news article edited and aggregated the press release and study, and was manually curated for mobile readers.